Viking Therapeutics Appoints Charles A. Rowland Jr. to Board of Directors
July 06, 2017 at 08:00 am EDT
Viking Therapeutics, Inc. announced the appointment of Charles A. Rowland Jr. to its board of directors. With more than 30 years of biopharmaceutical industry experience, Mr. Rowland provides Viking with broad expertise spanning financial management and strategic business operations. Currently a board member and strategic advisor for multiple biotechnology companies, Mr. Rowland was most recently the president and chief executive officer (CEO) of Aurinia Pharmaceuticals.